...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone
【24h】

A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone

机译：仅接受全脑放疗（WBRT）的脑转移患者的新生存率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose Survival scores for patients with brain metastasis exist. However, the treatment regimens used to create these scores were heterogeneous. This study aimed to develop and validate a survival score in homogeneously treated patients. Materials and methods Eight-hundred-and-eighty- two patients receiving 10 × 3 Gy of WBRT alone were randomly assigned to a test group (N = 441) or a validation group (N = 441). In the multivariate analysis of the test group, age, performance status, extracranial metastasis, and systemic treatment prior to WBRT were independent predictors of survival. The score for each factor was determined by dividing the 6-month survival rate (in %) by 10. Scores were summed and total scores ranged from 6 to 19 points. Patients were divided into four prognostic groups. Results The 6-month survival rates were 4% for 6-9 points, 29% for 10-14 points, 62% for 15-17 points, and 93% for 17-18 points (p < 0.001) in the test group. The survival rates were 3%, 28%, 54% and 96%, respectively (p < 0.001) in the validation group. Conclusions Since the 6-month survival rates in the validation group were very similar to the test group, this new score (WBRT-30) appears valid and reproducible. It can help making treatment choices and stratifying patients in future trials.
机译：背景和目的存在脑转移患者的生存评分。但是，用于创建这些分数的治疗方案是异类的。这项研究旨在发展和验证接受同等治疗的患者的生存评分。材料和方法八百八十二名仅接受10×3 Gy WBRT的患者被随机分配到测试组（N = 441）或验证组（N = 441）。在测试组的多因素分析中，WBRT之前的年龄，工作状态，颅外转移和全身治疗是生存的独立预测因素。通过将6个月生存率（％）除以10来确定每个因素的分数。将分数相加，总分在6到19分之间。将患者分为四个预后组。结果试验组的6个月生存率分别为6-9点为4％，10-14点为29％，15-17点为62％，17-18点为93％（p <0.001）。验证组的生存率分别为3％，28％，54％和96％（p <0.001）。结论由于验证组的6个月生存率与测试组非常相似，因此该新评分（WBRT-30）似乎有效且可重复。它可以帮助您做出治疗选择，并在以后的试验中对患者进行分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号